Zobrazeno 1 - 10
of 83
pro vyhledávání: '"T, Giannakakis"'
Autor:
A. Dimitrakopoulos, George Papastratis, T. Giannakakis, N. Tsavaris, H. Tsipras, H. Margaris, M. Vadiaka, Panagiotis Gouveris, Efstathios Papalambros, D. Karadima, C. Kosmas, Sofia Rokana, Aristidis Polyzos, N. Ziras
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:514-519
To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy.Irinotecan was randomly administe
Autor:
D. Mavroudis, C. Kosmas, S Papadouris, John Souglakos, Sophia Agelaki, V. Georgoulias, Kostas Kalbakis, Ch. Kouroussis, T. Giannakakis, N. Malamos
Publikováno v:
Oncology. 62:103-109
Aim: To define the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of the carboplatin-vinorelbine combination in pretreated patients with advanced breast cancer. Patients and Methods: Patients with histologically confirmed metast
Autor:
T. Giannakakis, D. Mavroudis, E. Sarra, M. Parashos, Sophia Agelaki, Nikolaos Ziras, Dora Hatzidaki, Th. Dimou, Nikos Androulakis, J. Vlachonikolis, V. Georgoulias, S. Kakolyris
Publikováno v:
European Journal of Cancer. 36:742-747
Docetaxel and carboplatin have shown in vitro and in vivo activity against non-small cell lung cancer (NSCLC). A phase I study was conducted in order to determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of their com
Autor:
G. Fountzilas, Nikolaos Dombros, K. Karakousis, Dimitris Bafaloukos, T. Giannakakis, P. Kosmidis, D.V. Skarlos, A. Athanassiades
Publikováno v:
European Journal of Cancer. 32:47-51
33 women with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 175 mg/m2 in a 3 h infusion every 3 weeks. The median age was 53 years (range 30-72) and the median performance status was 1 (range 0-2). 24 (73%) patients
Autor:
T. Giannakakis, Krystallenia I Alexandraki, Gregory Kaltsas, Chris Tsigris, Evangelos Felekouras, Nikoletta Dimitriou, John Griniatsos, K. I. Bramis, Nikiforos Ballian
Publikováno v:
Journal of endocrinological investigation. 34(4)
Background: Appendiceal carcinoids (AC) are usually adequately treated by appendectomy. The European Neuroendocrine Tumours Society (ENETS) has recently reconsidered the previous pathologic criteria to identify patients at high risk of extra-appendic
Autor:
Paris Kosmidis, M. Beer, A Kalogera-Fountzila, P. Makrantonakis, Nicholas Pavlidis, T. Giannakakis, George Fountzilas, Nikolaos Tsavaris, Dimosthenis Skarlos
Publikováno v:
Tumori Journal. 77:232-236
Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the median weekly dose 78% of the
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
C, Kouroussis, E, Xydakis, A, Potamianou, T, Giannakakis, S, Kakolyris, S, Agelaki, E, Sara, N, Malamos, A, Alexopoulos, D, Mavroudis, G, Samonis, S, Papadouris, V, Georgoulias, G, Panagos
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10(5)
To determine the maximum tolerable dose (MTD) and the dose-limiting toxicity (DLT) of docetaxel (D) in combination with epirubicin (Epi) in patients with advanced breast cancer.Forty-seven chemotherapy-naïve metastatic breast cancer patients aged75
Autor:
D, Mavroudis, N, Malamos, A, Alexopoulos, C, Kourousis, S, Agelaki, E, Sarra, A, Potamianou, C, Kosmas, G, Rigatos, T, Giannakakis, K, Kalbakis, F, Apostolaki, J, Vlachonicolis, S, Kakolyris, G, Samonis, V, Georgoulias
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10(2)
The activity of the docetaxel-gemcitabine combination in women with disease progression after initial chemotherapy for metastatic breast cancer (MBC) was investigated in a multicenter phase II study.Fifty-two patients with metastatic breast cancer wh
Autor:
C, Nicolaides, G, Fountzilas, N, Zoumbos, D, Skarlos, P, Kosmidis, D, Pectasides, A, Karabelis, T, Giannakakis, A, Symeonidis, A, Papadopoulos, F, Antoniou, N, Pavlidis
Publikováno v:
Oncology. 55(5)
Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently formulated. We tried to identify t